We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock

Delisted

GTHX was delisted on the 17th of September, 2024.

100 hedge funds and large institutions have $320M invested in G1 Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 19

14% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 29

2% more funds holding

Funds holding: 98100 (+2)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

60% less capital invested

Capital invested by funds: $798M → $320M (-$478M)

Holders
100
Holders Change
+2
Holders Change %
+2.04%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
22
Increased
33
Reduced
29
Closed
19
Calls
$31K
Puts
Net Calls
+$31K
Net Calls Change
+$4.08M

GTHX Hedge Fund Activity: Q1 2020 in Review

100 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2020, worth a combined $320M — down 60% from $798M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new GTHX positions and 19 closed out — a net gain of 3 holders — while 33 added to existing stakes and 29 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $7.86M. The largest seller was Wellington Management Group, cutting an estimated $27M.

  • 100 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2020, up from 98 in Q4 2019.
  • Funds reported $320M of G1 Therapeutics, Inc. Common Stock stock for Q1 2020, down 60% quarter-over-quarter.
  • 22 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2020 and 19 closed out, a net change of +3 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2020 was Deutsche Bank, an estimated $7.86M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2020 was Wellington Management Group, an estimated $27M sold.

Based on aggregated 13F filings for Q1 2020.